Publications by authors named "Sarah Ollis"

Article Synopsis
  • CHAPLE disease is a rare and serious condition affecting fewer than 100 young people worldwide, characterized by symptoms like abdominal pain and protein loss from the intestines.
  • A study used mixed methods, including interviews and clinical assessments, to evaluate the impact of pozelimab treatment on these symptoms over 24 weeks.
  • Results showed that after treatment, patients experienced complete resolution of core symptoms, highlighting the value of mixed-methods in understanding patient experiences in rare disease trials.
View Article and Find Full Text PDF

Introduction: Individuals living with Crohn's disease (CD) experience burdensome symptoms. As such, it is important to measure CD symptom severity in clinical research. The goal of this study was to evaluate the content validity, psychometric performance, and score interpretability of a new patient-reported instrument, the Crohn's Symptom Severity (CSS) questionnaire, among adolescents and adults with moderately to severely active CD.

View Article and Find Full Text PDF

Background: Patients with Crohn's disease (CD) or ulcerative colitis (UC) frequently experience fatigue, although it is often overlooked in medical research and practice.

Aims: To explore patients' experience of fatigue and evaluate content validity, psychometric properties, and score interpretability of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in patients with CD or UC.

Methods: Concept elicitation and cognitive interviews were conducted with participants aged ≥ 15 years with moderately-to-severely active CD (N = 30) or UC (N = 33).

View Article and Find Full Text PDF
Article Synopsis
  • The Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) is a 10-item tool designed to evaluate the severity of symptoms in patients with mitochondrial disease, assessing its psychometric properties based on data from a clinical trial.
  • Participants in the trial, mostly women with an average age of 45, filled out the PMMSA daily for about 14 weeks while testing elamipretide in a randomized, placebo-controlled study.
  • Results showed that while the PMMSA items did not form a single construct, four related to tiredness were grouped as a "general fatigue" score, which proved to be stable and correlated well with other health measures, with meaningful reductions being linked to symptom improvement.
View Article and Find Full Text PDF

Background: Barth Syndrome (BTHS) is a rare genetic disorder that presents as a complex of debilitating symptoms and reduced life expectancy. Well-developed, BTHS-specific assessments measuring primary signs and symptoms of BTHS are not currently available, making it difficult to evaluate treatment effects in BTHS clinical studies. The objective of this research was to develop symptom-focused patient-reported outcome (PRO) measures for use in clinical studies with adolescents and adults with BTHS.

View Article and Find Full Text PDF

Objectives: Primary mitochondrial myopathy (PMM) is a genetic condition characterized by life-limiting symptoms such as muscle weakness, fatigue, and pain. Because these symptoms are best reported by individuals with PMM, the objective of this qualitative research study was to develop a PMM-specific patient-reported outcome (PRO) questionnaire.

Method: Individuals with PMM were interviewed, identifying the most salient symptoms of PMM and assessing the resulting questionnaire's relevance and comprehensibility.

View Article and Find Full Text PDF

Background: Barth syndrome (BTHS, OMIM 302060) is a rare, life-threatening, x-linked genetic disorder that occurs almost exclusively in males and is characterized by cardiomyopathy, neutropenia, skeletal muscle myopathy primarily affecting larger muscles, and shorter stature in youth. A greater number of individuals with BTHS are now surviving into adulthood due to advancements in diagnosis and disease management. Given these improvements in life expectancy, understanding the disease experience over time has become increasingly important to individuals with the condition, treatment developers, and regulatory agencies.

View Article and Find Full Text PDF